Nektar presents data from Phase l study of etirinotecan pegol

theflyonthewall.com

Nektar presented favorable data today from a Phase 1 study of etirinotecan pegol, EP, NKTR-102, in combination with 5-fluorouracil, 5-FU/Leucovorin LV, in patients with advanced cancer. NKTR-102 is the first long-acting topoisomerase I-inhibitor designed to concentrate in tumor tissue, provide sustained tumor suppression throughout the entire chemotherapy cycle, and to reduce the peak exposures that are associated with toxicities of other cytotoxics. These new data were presented at the 2014 Gastrointestinal Cancers Symposium in San Francisco.

View Comments (0)